Chuck Triano | SVP, IR |
Dr. Albert Bourla | Chairman and CEO |
Frank D’Amelio | CFO |
Mikael Dolsten | Chief Scientific Officer and President, Worldwide Research Development and Medical |
Angela Hwang | Group President, Biopharmaceuticals Group |
John Young | Chief Business Officer |
Doug Lankler | General Counsel |
David Risinger | Morgan Stanley |
Steve Scala | Cowen |
Gregg Gilbert | Truist Securities |
Terence Flynn | Goldman Sachs |
Louise Chen | Cantor |
Umer Raffat | Evercore |
Geoffrey Porges | SVB Leerink |
Vamil Divan | Mizuho |
Tim Anderson | Wolfe Research |
Ronny Gal | Bernstein |
Navin Jacob | UBS |
Chris Schott | JP Morgan |
[Call Starts Abruptly] …Medical | Angela Hwang, Group President, Biopharmaceuticals Group - John Young, our Chief Business Officer - and Doug Lankler, General Counsel. |
The slides that will be presented on this call were posted to our website earlier this morning and are available at pfizer.com/investors. You'll see here on slide three | our disclaimer regarding forward looking statements we will make during this call regarding - among other topics - our anticipated future operating and financial performance - business plans and prospects - and expectations for our product pipeline and in-line products - which of course are subject to risks and uncertainties. |
In addition | we'll be using non-GAAP financial information. Additional information regarding forward-looking statements and our non-GAAP financial measures is available with our earnings release including under the Disclosure Notice section and under Risk Factors in our SEC Forms 10-K and 10-Q. |
The forward-looking statements on this call speak only as of the original date of this call | and we undertake no obligation to update or revise any of the statements. Albert and Frank will now make prepared remarks. And then - we'll move to a question-and-answer session. |
With that I'll now turn the call over to Albert Bourla. Albert? |
Thank you, Chuck, and good morning, everyone. 2020 was a year like none other in Pfizer’s history.
With the separation of Upjohn complete, we saw the culmination of Pfizer’s decade-long conversion into a pure-play, science and innovation-focused Company. Through our collaboration with BioNTech, we delivered the world’s first breakthrough COVID-19 vaccine in less than a year. And by harnessing the power of variety of digital capabilities, we made sure that despite the lockdowns and travel restrictions, we continue to serve patients around the world who rely on our medicines and vaccines.